ABSTRACT -Creutzfeldt-Jakob disease (CJD), the most known human prion disease, is usually sporadic but approximately 15% of the cases are familial. To date, seven CJD cases with codon 210 mutation (GTT to ATT) have been reported in the literature. We describe a case of a 57 year-old woman who presented gait disturbances and rapidly progressive dementia, leading to death four months after onset. Electroencephalogram revealed periodic activity, diffusion-weighted magnetic resonance imaging showed hypersignal in basal ganglia, and test for 14-3-3 protein was strongly positive in the CSF. The complete prion protein gene coding region was sequenced after PCR amplification, showing a point mutation in codon 210. This is the first case of CJD with codon 210 mutation diagnosed in Brazil. We emphasize the role of genetic search for prion protein gene mutation, even in patients presenting clinical features resembling sporadic CJD.
Creutzfeldt-Jakob disease (CJD) is the most well known human prion disease, a group of diseases related to the presence of the pathologic prion protein (PrP Sc ) in brain tissue 1 . The incidence of CJD is approximately 1 case per million inhabitants annually. The clinical picture includes a rapidly progressive dementia, myoclonus, and pyramidal, extrapyramidal or cerebellar syndromes 2 . Electroencephalogram (EEG) may show periodic activity in approximately 65% of cases, with a specificity of 86% 3, 4 . The presence of 14-3-3 protein in the cerebrospinal fluid (CSF), together with suggestive clinical features, has been considered highly sensitive and specific for diagnosis 4, 5 . However, definitive diagnosis is still dependent on pathological confirmation of the presence of PrP Sc in brain tissue. About 15% of CJD cases are familial, associated with point mutations or insertions in the prion protein gene, which is located in the short arm of chromossome 20. The clinical features and neuropathological findings tend to vary, depending on the different mutations. Codon 129 polymorphysms are also linked to CJD risk, clinical phenotype and prognosis [6] [7] [8] . Our main objective is to report the first case of CJD associated with codon 210 mutation (V210I) diagnosed in Brazil. Data from this patient were previously reported emphasizing neuroimaging findings 9 .
CASE
A 57-year old woman, born in Germany and residing in Brazil, developed dizziness which was soon followed by gait and speech disturbances. A consultant neurologist detected a global cerebellar syndrome so requested laboratory tests and a brain CT-scan that on examination proved unremarkable. Her gait deteriorated and a rapidly progressive cognitive decline associated with myoclonic jerks became evident. A routine brain MRI was reported as normal. When she was first seen by us, two months after the onset of her symptoms, she was alert but unable to follow simple commands, with no eye-blinking to threatening stimuli, while reacting to painful stimuli by simply withdrawing the stimulated segment of body. She manifested spontaneous and startle myoclonus, increased tone with cogwheel rigidity in the arms, bilateral grasping reflex, and Babinski sign in the right foot. Routine blood tests and CSF analysis were within normal limits.
One of her sisters had died one year earlier, in Germany, with neuropathologically confirmed CJD. As far as we have been informed, no other members of the family have been affected by similar disease.
EEG revealed 1Hz periodic sharp waves (Fig 1) . MRI showed mild high signal in the striatum on T2-weighted images, whereas diffusion-weighted MRI (DWI) showed high signal in the striatum, cortical areas of the insulas, left temporal lobe, and the borderland between frontal and parietal lobes, bilaterally. The 14-3-3 protein immunoassay in CSF was performed as described by Zerr et al. 10 . 15 µl of CSF were applied to Western Blot. Detection of the bound polyclonal antibody to the β-isoforms of the 14-3-3 protein (Santa Cruz Biotech, USA) was performed using the enhanced chemiluminescence detection kit (Amersham, USA). A positive control from the NIH3T3 cell line and a negative control were run on every gel. For this patient, 14-3-3 protein was positive in the CSF sample (Fig 2) .
Genomic DNA was extracted from peripheral blood leukocytes by standard methods 11 following the informed consent of family members. The complete PRNP coding region was sequenced by obtaining two frag- ments after PCR amplification. The fragment from open reading frame to codon 134 was amplified, using the pair of primers F A (5'-CTGACGTTCTCCTCTTCATTTTG-3') and R A (5'-CTCATGGCACTTCCCAGCATGTA-3'). The cycle conditions were set ats 94°C for 30sec, 63°C for 30sec, and 72°C for 1 min. The PCR reactions were carried out for 30 cycles. The fragment from codon 107 to final of PRNP coding region was amplified, using the pair of primers F B (5'-AACCAACATGAAGCACATGG-3') and R B (5'-TCCCTCAAGCTGGAAAAAGA-3'). The cycle conditions were set at 94°C for 30 sec, 55°C for 30 sec and 72°C for 1 min. The PCR reactions were carried out for 35 cycles. We found a point mutation causing a substitution of valine by isoleucine in codon 210 (GTT-ATT) (Fig.3) and heterozigosity at codon 129 of the prion protein gene.
The patient died four months after onset of the symptoms. Autopsy was not performed.
DISCUSSION
Familial CJD associated with V210I mutation was first reported by Ripoll et al. 12 , and by Pochiari et al., in 1993 13 . Including these original cases, a total of 7 such cases with this mutation have been reported in the literature to date: one French patient 12 , one Italian family with two cases 13 , one Japanese patient 14 , two Chinese cases from the same family 15 and one individual from North Africa 16 .
The clinical and neuropathological features described in the Italian, French and Japanese patients were very similar to those of sporadic CJD with a rapid evolution to death (mean, 4.1 months) [12] [13] [14] . However, the Italian case had a new 24-bp delection in the other allele 13 . One of the Chinese patients presented with panencephalitis at the age of 48 years, and the disease duration exceeded 24 months 15 . The patient from North Africa presented sensory symptoms as the first manifestation, a finding that is prominent in the new variant of CJD(nvCJD) 17 , and died 7.5 months after the onset of the disease 16 .
There have also been reports of individuals bearing V210I mutation who had remained asymptomatic at 72 and 82 years of age 13, 16 , showing an incomplete penetrance.
Polymorphism at codon 129 is linked to both susceptibility to prion diseases, and to different clinical features 8 . For example, all nvCJD cases reported so far were homozygous for methionine at codon 129 .17 , and homozygosity at this codon is a predisposing risk factor to for sporadic and iatrogenic CJD. In different mutations of the prion protein gene, 129 polymorphism has been described as a factor that could modify survival time 18 . The influence of 129 polymorphism on 210 mutation phenotype has not been established 8 . Five out of the seven cases with the 210 mutation described to date, were methionine homozygous at the codon 129 [13] [14] [15] [16] . One of the Italian cases and the French patient did not undergo 129 polymorphism determination.
In the case we are reporting, apart from the heterozygosity at codon 129, the clinical picture and evolution were typical of sporadic CJD associated with type 1 PrP Sc and methionine homozygosity at codon 129. This being characterized by a rapidly progressive dementia with myoclonus and periodic sharp waves on EEG 19, 20 . MRI in this patient showed the typical findings of high signal in basal ganglia and in a few cortical areas that have been described in CJD, and which are more evident in diffusion-weighted MRI 9, 21 .
Recently, 14-3-3 protein in the CSF was described as an important marker of CJD 4 . In this patient, the strong positive reaction of the 14-3-3 protein is possibly related to the rapid and progressive destruction of the brain tissue.
We emphasize the importance of genetic investigation to search for prion protein gene mutations, even in patients presenting typical clinical features resembling sporadic CJD.
